These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32944406)

  • 1. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
    Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
    Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
    Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
    Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma
    Lu Y; Li P; Zhou Y; Zhang J
    Curr Cancer Drug Targets; 2023; 23(6):496-504. PubMed ID: 36748214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
    Feng Y; Sassi S; Shen JK; Yang X; Gao Y; Osaka E; Zhang J; Yang S; Yang C; Mankin HJ; Hornicek FJ; Duan Z
    J Orthop Res; 2015 Feb; 33(2):199-207. PubMed ID: 25348612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.
    Chen W; Lin Y; Jiang M; Wang Q; Shu Q
    J Transl Med; 2022 Aug; 20(1):355. PubMed ID: 35962451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
    Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
    Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
    Kiessling MK; Schuierer S; Stertz S; Beibel M; Bergling S; Knehr J; Carbone W; de Vallière C; Tchinda J; Bouwmeester T; Seuwen K; Rogler G; Roma G
    BMC Genomics; 2016 Sep; 17(1):723. PubMed ID: 27613601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
    Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
    Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
    Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
    J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
    Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
    Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
    J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
    Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
    Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
    J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells.
    Kamptner AZM; Mayer CE; Sutterlüty H
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
    Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
    Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidic Cell Deformability Assay for Rapid and Efficient Kinase Screening with the CRISPR-Cas9 System.
    Han X; Liu Z; Zhao L; Wang F; Yu Y; Yang J; Chen R; Qin L
    Angew Chem Int Ed Engl; 2016 Jul; 55(30):8561-5. PubMed ID: 27258939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
    Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
    Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-1285-3p is a potential prognostic marker in human osteosarcoma and functions as a tumor suppressor by targeting YAP1.
    Hu XH; Dai J; Shang HL; Zhao ZX; Hao YD
    Cancer Biomark; 2019; 25(1):1-10. PubMed ID: 31006663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
    Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
    PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.